Mirum Pharmaceuticals (MIRM) CFO sells shares for tax withholding

Rhea-AI Filing Summary

Mirum Pharmaceuticals’ chief financial officer Eric Bjerkholt reported routine equity compensation activity. On January 23, 2026, 2,667 restricted stock units vested and converted into the same number of common shares at an exercise price of $0. On January 26, 2026, he sold 1,053 of these shares at $96.192 per share to cover tax withholding obligations linked to the vesting. After these transactions, he directly owns 43,741 shares of common stock and 2,666 restricted stock units, which continue to vest in equal annual installments through the three-year schedule that began January 23, 2024.

Insider Trade Summary

Net Seller: 1,053 shares ($101,290)

Net Sell 3 txns

Insider BJERKHOLT ERIC

Role CHIEF FINANCIAL OFFICER

Sold 1,053 shs ($101K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,053	$96.192	$101K
Exercise	Restricted Stock Units	2,667	$0.00	--
Exercise	Common Stock	2,667	$0.00	--

Holdings After Transaction: Common Stock — 43,741 shares (Direct); Restricted Stock Units — 2,666 shares (Direct)

Footnotes (1)

1. Each restricted stock unit represents a contingent right to receive one share of common stock (or its cash equivalent, at the discretion of the Issuer). Shares sold to cover tax withholding obligations associated with the vesting of restricted stock units. 1/3rd of the shares subject to the restricted stock units shall vest on each anniversary of January 23, 2024 (the "Vesting Commencement Date"), such that the entire award will be vested on the three-year anniversary of the Vesting Commencement Date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BJERKHOLT ERIC

(Last) (First) (Middle)

C/O MIRUM PHARMACEUTICALS, INC.

989 E HILLSDALE BLVD., SUITE 300

(Street)

FOSTER CITY CA 94404

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Mirum Pharmaceuticals, Inc. [ MIRM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF FINANCIAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
01/23/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/23/2026		M		2,667	A	(1)	44,794	D
Common Stock	01/26/2026		S(2)		1,053	D	$96.192(1)	43,741	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	01/23/2026		M			2,667	(3)	(3)	Common Stock	2,667	$0	2,666	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of common stock (or its cash equivalent, at the discretion of the Issuer).

2. Shares sold to cover tax withholding obligations associated with the vesting of restricted stock units.

3. 1/3rd of the shares subject to the restricted stock units shall vest on each anniversary of January 23, 2024 (the "Vesting Commencement Date"), such that the entire award will be vested on the three-year anniversary of the Vesting Commencement Date.

	/s/ Judit Ryvkin, Attorney-in-Fact	01/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Mirum Pharmaceuticals (MIRM) report for its CFO?

Mirum Pharmaceuticals reported that CFO Eric Bjerkholt had restricted stock units vest and then sold some resulting shares. He exercised 2,667 RSUs into common stock and later sold 1,053 shares, primarily to cover tax withholding obligations associated with the RSU vesting event.

How many Mirum Pharmaceuticals (MIRM) shares did the CFO sell and at what price?

The CFO sold 1,053 Mirum Pharmaceuticals common shares at a price of $96.192 per share. This sale occurred on January 26, 2026 and was disclosed as covering tax withholding obligations tied to recently vested restricted stock units awarded as part of his compensation.

How many Mirum Pharmaceuticals (MIRM) shares and RSUs does the CFO now hold?

Following the reported transactions, the CFO directly holds 43,741 shares of Mirum common stock and 2,666 restricted stock units. These positions reflect the RSU vesting on January 23, 2026 and the subsequent sale of 1,053 shares used to satisfy related tax withholding requirements.

What are the terms of the CFO’s Mirum Pharmaceuticals (MIRM) restricted stock units?

Each restricted stock unit gives the right to receive one Mirum common share or its cash equivalent. One-third of the RSU award vests on each anniversary of January 23, 2024, so the entire grant becomes fully vested on the three-year anniversary of that vesting commencement date.

Why were some Mirum Pharmaceuticals (MIRM) shares sold after the RSUs vested?

The filing explains that the 1,053 shares were sold to cover tax withholding obligations from the RSU vesting. When restricted stock units convert into shares, income taxes are typically due, and selling a portion of the new shares is a common way to satisfy that liability.

How do Mirum Pharmaceuticals (MIRM) RSUs convert into common stock for the CFO?

Each RSU represents a contingent right to receive one Mirum common share or cash at the issuer’s discretion. When vesting conditions are met, RSUs convert into common stock at a $0 exercise price, creating taxable income and increasing the executive’s directly owned share count accordingly.